Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMS5552 Multiple Ascending Dose Study in Type 2 Diabetes
NCT02077452Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Mar 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dorzagliatin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Hua Medicine. Primary endpoint: Safety and tolerability of HMS5552 up to 15 days. Started Mar 2014; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02077452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077452.